StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Tecfidera IP the Major Risk of Biogen (BIIB) Takeout - Baird
August 3, 2016 7:17 AM
Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB) amid reports Tuesday that the company is in talks with ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Mergers and Acquisitions
Rumors
Next Articles
Biogen (BIIB) Sale Dependent on Value of Aducanumab - BMO Capital
August 3, 2016 7:52 AM
Biogen (BIIB) Takeover 'Makes Sense' - Leerink Partners
August 3, 2016 7:38 AM
Allergan (AGN) unlikely to pursue Biogen (BIIB) deal - source - CNBC
August 2, 2016 5:26 PM
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
August 2, 2016 3:41 PM
Biogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ
August 2, 2016 2:43 PM